1541 — ImmuneOnco Biopharmaceuticals Shanghai Cashflow Statement
0.000.00%
- HK$2.66bn
- HK$2.00bn
- CNY74.15m
Annual cashflow statement for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | |
Standards: | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | -733 | -403 | -379 | — |
Depreciation | ||||
Non-Cash Items | 555 | 134 | 75.4 | — |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -25.7 | 12.5 | -86.1 | — |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Accounts Payable | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -191 | -239 | -368 | — |
Capital Expenditures | -125 | -23.2 | -2.69 | — |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 16.5 | 23.3 | -292 | — |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -109 | 0.049 | -295 | — |
Financing Cash Flow Items | -3.17 | -4.39 | -30.5 | — |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 793 | 179 | 331 | — |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 485 | -33.1 | -328 | — |